New Patent Filed by Adial Pharmaceuticals for AD04, Extending Asset Protection

Adial Pharmaceuticals, a clinical-stage biopharmaceutical company that specialises in creating treatments for addiction and associated disorders, has announced the submission of a new patent application for AD04, the company's lead investigational therapeutic agent for treating Alcohol Use Disorder (AUD) in patients who drink heavily (defined as < 10 drinks per day). AD04 is a genetically targeted serotonin-3 receptor antagonist. Assuming the patent is approved, Adial's primary assets should be safeguarded until at least 2044.

"As we continue to advance the AD04 program with the progress of our pharmacokinetics study of AD04, this new patent application and its expected approval will extend protection of the core assets of Adial out to at least 2044," stated Cary Claiborne, President and Chief Executive Officer of Adial. This application is the outcome of a thorough investigation of data and information that took place following Adial's hiring of new patent counsel with the goal of strengthening and optimising the business's intellectual property portfolio.